Among those, 12/42 (28.6%) had a median SUVmax above 10 (ACC, 5/12 [41.7%]; neuroendocrine neoplasms, 4/12 [33.3%]; SCLC, 2/12 [16.7%]; DSCRT, 1/12 [8.3%]), thereby possibly rendering those patients eligible for CXCR4-targeted “cold” inhibitory drugs or RLT. Here, CXCR4 is linked to neuroendocrine neoplasm.